CCM
FULC icon

Cinctive Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Cinctive Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-57,700
Closed -$1.36M – 547
2022
Q1 		$1.36M Buy
+57,700
New +$817K 0.05% 372

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cinctive Capital Management's FULC Position: Q2 2022 in Review

Cinctive Capital Management sold out of Fulcrum Therapeutics (FULC) in Q2 2022, closing a stake of 66,120 shares — an estimated $1.56M sold.

Cinctive Capital Management first reported a position in FULC in Q4 2021 and held it in 2 quarters. The position peaked at $1.56M in Q1 2022. 101 funds tracked by Wall St. Rank hold FULC as of Q2 2022.

  • Cinctive Capital Management reported no remaining Fulcrum Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cinctive Capital Management sold 66,120 Fulcrum Therapeutics shares in Q2 2022, an estimated $1.56M.
  • Cinctive Capital Management first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 2 quarters.
  • Cinctive Capital Management's Fulcrum Therapeutics position peaked at $1.56M in Q1 2022.
  • 101 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2022.

Based on Cinctive Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.